Our Chinese clients are actively seeking oversea licensing partners. If the collaboration with China aligns with your corporate strategic plan, please request 30 minutes partnering consultation with Ginger Ding for further information.
- List of Companies That Seek for Oversea Partners
Hengrui Medicine established in 1970, having over 13,000 employees globally, is the largest manufacturer of antineoplastics in China. Its operating income was over USD 1.7 billion in 2016.
Objective: In-licensing opportunities for innovative drugs, regardless of developmental stages, in oncology, autoimmune, diabetes, metabolic and cardiovascular diseases.
Fosun Pharma manufactures pharmaceutical products. The Company produces genetic medicines, Chinese traditional medicines, diagnostic products, reagents, and other products.
Objective: In-licensing opportunities for phase III stage drugs, in oncology, cardiovascular disease, CNS, liver disease
Simcere Pharma was founded on March 28, 1995, with an enterprise mission to “discover and develop high-quality medicines for patients.” Since its inception, we have grown from a registered capital of 2.78 million to total assets of over 3 billion yuan, from a few dozen people to an R&D-driven pharmaceutical enterprise with more than 3,000 talents, and from an annual tax of less than a million to about 500 million yuan.
Objective: In-licensing opportunities for innovative drugs, regardless of developmental stage, in oncology, CNS and metabolic diseases
Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.
Objective: In-licensing opportunities for cancer drugs